5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson’s disease
| Autor: | Marcus C. Ferguson, Twum A. Ansah, Tultul Nayyar, Ariel Y. Deutch |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Levodopa Indoles Parkinson's disease Pyridines medicine.drug_class Ritanserin Pharmacology Article Antiparkinson Agents Disability Evaluation Mice Cellular and Molecular Neuroscience chemistry.chemical_compound Parkinsonian Disorders Piperidines medicine Serotonin 5-HT2 Receptor Antagonists Animals Dyskinesias SB-206553 Dose-Response Relationship Drug MPTP Antagonist Brain Parkinson Disease Receptor antagonist medicine.disease Fluorobenzenes Mice Inbred C57BL Disease Models Animal Treatment Outcome chemistry Serotonin Antagonists Psychology Neuroscience medicine.drug |
| Zdroj: | Neuropharmacology. 59:31-36 |
| ISSN: | 0028-3908 |
| DOI: | 10.1016/j.neuropharm.2010.03.013 |
| Popis: | Clinical observations have suggested that ritanserin, a 5-HT(2A/C) receptor antagonist may reduce motor deficits in persons with Parkinson's Disease (PD). To better understand the potential antiparkinsonian actions of ritanserin, we compared the effects of ritanserin with the selective 5-HT(2A) receptor antagonist M100907 and the selective 5-HT(2C) receptor antagonist SB 206553 on motor impairments in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP-treated mice exhibited decreased performance on the beam-walking apparatus. These motor deficits were reversed by acute treatment with L-3,4-dihydroxyphenylalanine (levodopa). Both the mixed 5-HT(2A/C) antagonist ritanserin and the selective 5-HT(2A) antagonist M100907 improved motor performance on the beam-walking apparatus. In contrast, SB 206553 was ineffective in improving the motor deficits in MPTP-treated mice. These data suggest that 5-HT(2A) receptor antagonists may represent a novel approach to ameliorate motor symptoms of Parkinson's disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect